Evidence map›Paper›PMID 30621556›Full record

ReviewCurrent medicinal chemistry2019

Nano-biofilm Arrays as a Novel Universal Platform for Microscale Microbial Culture and High-Throughput Downstream Applications.

Anand Srinivasan, Anand K Ramasubramanian, José L Lopez-Ribot

Open access · greenAbstract readReview
In one paragraph

Review in Current medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anand SrinivasanBioBridge Global, San Antonio, TX, 78201, United States.
Anand K RamasubramanianDepartment of Biomedical, Chemical and Materials Engineering, San José State University, San José, CA, 95192, United States.
José L Lopez-RibotDepartment of Biology and South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, TX, 78249, United States.
The University of Texas at San Antonio · US

Funding

Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR002645 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2018 to 2022
$20.4M
Institute for Integration of Medicine & Science: A Partnership to Improve HealthUL1TR001120 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CLARK, ROBERT A, HARGREAVES, KENNETH M · 2013 to 2017
$16.5M
Development of novel chemical series of Candida albicans biofilm inhibitorsR01AI119554 · NIAID · UNIVERSITY OF TEXAS SAN ANTONIO · PI LOPEZ-RIBOT, JOSE L., MCHARDY, STANTON FURST · 2015 to 2019
$1.8M
Targeting virulence against oral candidiasis in HIV/AIDSR01DE023510 · NIDCR · UNIVERSITY OF TEXAS SAN ANTONIO · PI LOPEZ-RIBOT, JOSE L. · 2013 to 2017
$1.8M
NCATS NIH HHS UL1 TR001120NCATS NIH HHS UL1 TR002645NIAID NIH HHS R01 AI119554NIDCR NIH HHS R01 DE023510
6 · The paper itself

Abstract

Biofilms are the predominant mode of microbial growth and it is now fully accepted that a majority of infections in humans are associated with a biofilm etiology. Biofilms are defined as attached and structured microbial communities surrounded by a protective exopolymeric matrix. Importantly, sessile microorganisms growing within a biofilm are highly resistant to antimicrobial agents. Thus, there is an urgent need to develop new and improved anti-biofilm therapies. Unfortunately, most of the current techniques for in-vitro biofilm formation are not compatible with high throughput screening techniques that can speed up discovery of new drugs with anti-biofilm activity. To try to overcome this major impediment, our group has developed a novel technique consisting of micro-scale culture of microbial biofilms on a microarray platform. Using this technique, hundreds to thousands of microbial biofilms, each with a volume of approximately 30-50 nanolitres, can be simultaneously formed on a standard microscope slide. Despite more than three orders of magnitude of miniaturization over conventional biofilms, these nanobiofilms display similar growth, structural and phenotypic properties, including antibiotic drug resistance. These nanobiofilm chips are amenable to automation, drastically reducing assay volume and costs. This technique platform allows for true high-throughput screening in search for new anti-biofilm drugs.

Indexed as

BiofilmsNanotechnologyAnti-Infective AgentsHigh-Throughput Screening AssaysHumansAnti-Infective Agentsbiofilm chipBiofilmsdrug developmenthigh throughput screeningmicroarraymicroscale culture.

Identifiers

PMID30621556
PMCPMC6612466
OpenAlexW2910802409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.